Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial.
Cintra RMR, Soares AAS, Breder I, Munhoz DB, Barreto J, Kimura-Medorima ST, Cavalcante P, Zanchetta R, Breder JC, Moreira C, Virginio VW, Bonilha I, Lima-Junior JC, Coelho-Filho OR, Wolf VLW, Guerra-Junior G, Oliveira DC, Haeitmann R, Fernandes VHR, Nadruz W, Chaves FRP, Arieta CEL, Quinaglia T, Sposito AC; ADDENDA-BHS2 trial investigators. Cintra RMR, et al. Diabetol Metab Syndr. 2019 Jul 31;11:62. doi: 10.1186/s13098-019-0457-3. eCollection 2019. Diabetol Metab Syndr. 2019. PMID: 31384310 Free PMC article.
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Wolf VLW, Breder I, de Carvalho LSF, Soares AAS, Cintra RM, Barreto J, Munhoz DB, Kimura-Medorima ST, Nadruz W, Guerra-Júnior G, Quinaglia T, Muscelli E, Sposito AC; Addenda-BHS2 trial investigators. Wolf VLW, et al. Nutr Diabetes. 2021 Jun 12;11(1):17. doi: 10.1038/s41387-021-00160-5. Nutr Diabetes. 2021. PMID: 34120150 Free PMC article. Clinical Trial.
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Bonilha I, Oliveira DC, Breder JC, Cavalcante P, Moreira C, Moura FA, de Lima-Junior JC, do Carmo HRP, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T; ADDENDA-BHS2 trial investigators. Sposito AC, et al. Cardiovasc Diabetol. 2021 Mar 26;20(1):74. doi: 10.1186/s12933-021-01264-z. Cardiovasc Diabetol. 2021. PMID: 33771149 Free PMC article. Clinical Trial.
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Breder I, Wolf VLW, Soares AAS, de Carvalho LSF, Kimura-Medorima ST, Cintra RM, Barreto J, Munhoz DB, Cunha JS, Bonilha I, Coelho-Filho OR, Quinaglia T, Nadruz W, Guerra-Junior G, Muscelli E, Sposito AC; ADDENDA-BHS2 Trial Investigators. Breder I, et al. Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19. Diabetes Metab. 2022. PMID: 34808345 Clinical Trial. No abstract available.
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
Fernandes VHR, Chaves FRP, Soares AAS, Breder I, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Breder JC, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T, Arieta CEL, Sposito AC; ADDENDA-BHS2 trial investigators. Fernandes VHR, et al. Diabetes Metab. 2021 Nov;47(6):101280. doi: 10.1016/j.diabet.2021.101280. Epub 2021 Sep 16. Diabetes Metab. 2021. PMID: 34537385 Clinical Trial.